|
US6080216A
(en)
*
|
1998-04-22 |
2000-06-27 |
3M Innovative Properties Company |
Layered alumina-based abrasive grit, abrasive products, and methods
|
|
EP1688420A4
(en)
*
|
2003-11-19 |
2008-10-22 |
Japan Tobacco Inc |
5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR
|
|
US20070049593A1
(en)
*
|
2004-02-24 |
2007-03-01 |
Japan Tobacco Inc. |
Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
|
|
US7795247B2
(en)
*
|
2004-10-26 |
2010-09-14 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Tetracyclic indole derivatives as antiviral agents
|
|
AU2005298403A1
(en)
*
|
2004-10-26 |
2006-05-04 |
Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Tetracyclic indole derivatives as antiviral agents
|
|
US7659263B2
(en)
|
2004-11-12 |
2010-02-09 |
Japan Tobacco Inc. |
Thienopyrrole compound and use thereof as HCV polymerase inhibitor
|
|
AU2006242475B2
(en)
|
2005-05-02 |
2011-07-07 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
|
JP4705984B2
(ja)
|
2005-08-01 |
2011-06-22 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Hcvns3プロテアーゼ阻害剤としての大環状ペプチド
|
|
GB0518390D0
(en)
*
|
2005-09-09 |
2005-10-19 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
US7399758B2
(en)
*
|
2005-09-12 |
2008-07-15 |
Meanwell Nicholas A |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
|
US7473688B2
(en)
|
2005-09-13 |
2009-01-06 |
Bristol-Myers Squibb Company |
Indolobenzazepine HCV NS5B inhibitors
|
|
WO2007092000A1
(en)
*
|
2006-02-06 |
2007-08-16 |
Bristol-Myers Squibb Company |
Inhibitors of hcv replication
|
|
US7456165B2
(en)
|
2006-02-08 |
2008-11-25 |
Bristol-Myers Squibb Company |
HCV NS5B inhibitors
|
|
GB0608928D0
(en)
*
|
2006-05-08 |
2006-06-14 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
|
GB0609492D0
(en)
|
2006-05-15 |
2006-06-21 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
|
US7521443B2
(en)
*
|
2006-05-17 |
2009-04-21 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
|
CN101443336B
(zh)
*
|
2006-05-17 |
2012-07-04 |
百时美施贵宝公司 |
环丙基稠合的[吲哚]并[苯并氮杂*]hcv ns5b抑制剂
|
|
US7456166B2
(en)
*
|
2006-05-17 |
2008-11-25 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
|
US7521441B2
(en)
*
|
2006-05-22 |
2009-04-21 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
|
US7521442B2
(en)
|
2006-05-25 |
2009-04-21 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
|
CN101490054B
(zh)
*
|
2006-05-25 |
2012-05-16 |
百时美施贵宝公司 |
环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
|
|
US7452876B2
(en)
|
2006-06-08 |
2008-11-18 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
|
GB0612423D0
(en)
|
2006-06-23 |
2006-08-02 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
|
EP2374812B1
(en)
|
2006-07-13 |
2015-04-15 |
Achillion Pharmaceuticals, Inc. |
4-amino-4-oxobutanoyl Peptides as Inhibitors of Viral Replication
|
|
KR20090029827A
(ko)
*
|
2006-07-20 |
2009-03-23 |
제네랩스 테크놀로지스, 인코포레이티드 |
폴리사이클릭 바이러스 억제제
|
|
EP2079480B1
(en)
|
2006-10-24 |
2013-06-05 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
|
AU2007309544B2
(en)
|
2006-10-24 |
2012-05-31 |
Msd Italia S.R.L. |
HCV NS3 protease inhibitors
|
|
AU2007309546A1
(en)
|
2006-10-24 |
2008-05-02 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
HCV NS3 protease inhibitors
|
|
AU2007318165B2
(en)
|
2006-10-27 |
2011-11-17 |
Msd Italia S.R.L. |
HCV NS3 protease inhibitors
|
|
EP2083844B1
(en)
|
2006-10-27 |
2013-11-27 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
|
EP2121707B1
(en)
*
|
2006-12-20 |
2012-12-05 |
Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. |
Antiviral indoles
|
|
GB0625349D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
GB0625345D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
MX2009006877A
(es)
|
2006-12-22 |
2009-09-28 |
Schering Corp |
Derivados indolicos con anillo unido en las posiciones 5,6 y metodos de uso de los mismos.
|
|
CA2673254C
(en)
|
2006-12-22 |
2013-09-10 |
Schering Corporation |
4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
|
|
RU2009127855A
(ru)
*
|
2006-12-22 |
2011-01-27 |
Шеринг Корпорейшн (US) |
4,5 циклоаннелированные производные индола для лечения или предотвращения вируса гепатита с (hcv) и родственных вирусных инфекций
|
|
US7541351B2
(en)
*
|
2007-01-11 |
2009-06-02 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
US7541352B2
(en)
*
|
2007-02-02 |
2009-06-02 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
US7517872B2
(en)
*
|
2007-02-22 |
2009-04-14 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
CA2679377A1
(en)
*
|
2007-02-26 |
2008-09-04 |
Achillion Pharmaceuticals, Inc. |
Tertiary amine substituted peptides useful as inhibitors of hcv replication
|
|
AU2008219622A1
(en)
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors
|
|
US7998951B2
(en)
*
|
2007-03-05 |
2011-08-16 |
Bristol-Myers Squibb Company |
HCV NS5B inhibitors
|
|
JP5211078B2
(ja)
*
|
2007-03-13 |
2013-06-12 |
ブリストル−マイヤーズ スクイブ カンパニー |
シクロプロピル縮合インドロベンズアゼピンhcvns5b阻害剤
|
|
US7521444B2
(en)
*
|
2007-03-14 |
2009-04-21 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
US7541353B2
(en)
*
|
2007-03-14 |
2009-06-02 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
US7547690B2
(en)
*
|
2007-03-14 |
2009-06-16 |
Bristol-Myers Squibb Company |
Compounds for the treatment of Hepatitis C
|
|
US7538102B2
(en)
|
2007-03-14 |
2009-05-26 |
Bristol-Myers Squibb Company |
Compounds for the treatment of Hepatitis C
|
|
US7538103B2
(en)
*
|
2007-03-15 |
2009-05-26 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
|
EP2494991A1
(en)
|
2007-05-04 |
2012-09-05 |
Vertex Pharmaceuticals Incorporated |
Combination therapy for the treatment of HCV infection
|
|
CN101801982A
(zh)
*
|
2007-07-17 |
2010-08-11 |
P.安杰莱蒂分子生物学研究所 |
用于治疗丙型肝炎感染的大环吲哚衍生物
|
|
US8927569B2
(en)
|
2007-07-19 |
2015-01-06 |
Merck Sharp & Dohme Corp. |
Macrocyclic compounds as antiviral agents
|
|
US7652004B2
(en)
*
|
2007-08-09 |
2010-01-26 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
US8143243B2
(en)
*
|
2007-08-09 |
2012-03-27 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
US7642251B2
(en)
|
2007-08-09 |
2010-01-05 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
CN101821252A
(zh)
|
2007-08-29 |
2010-09-01 |
先灵公司 |
取代的吲哚衍生物及其使用方法
|
|
MX2010002316A
(es)
*
|
2007-08-29 |
2010-03-22 |
Schering Corp |
Derivados tetraciclicos de indol y su uso para el tratamiento o prevencion de infecciones virales.
|
|
PE20090995A1
(es)
|
2007-08-29 |
2009-08-03 |
Schering Corp |
Derivados indolicos 2,3-sustituidos como inhibidores del virus de la hepatitis c (vhc)
|
|
PE20090994A1
(es)
|
2007-08-29 |
2009-08-03 |
Schering Corp |
Derivados de azaindol 2,3-sustituidos como agentes antivirales
|
|
WO2009064848A1
(en)
|
2007-11-16 |
2009-05-22 |
Schering Corporation |
3-heterocyclic substituted indole derivatives and methods of use thereof
|
|
WO2009064852A1
(en)
|
2007-11-16 |
2009-05-22 |
Schering Corporation |
3-aminosulfonyl substituted indole derivatives and methods of use thereof
|
|
US8124601B2
(en)
|
2007-11-21 |
2012-02-28 |
Bristol-Myers Squibb Company |
Compounds for the treatment of Hepatitis C
|
|
US8129367B2
(en)
*
|
2007-11-21 |
2012-03-06 |
Bristol-Myers Squibb Company |
Compounds for the treatment of Hepatitis C
|
|
EA201000948A1
(ru)
|
2007-12-19 |
2011-02-28 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Ингибиторы вирусной полимеразы
|
|
AU2008339917B2
(en)
|
2007-12-24 |
2013-02-07 |
Tibotec Pharmaceuticals |
Macrocyclic indoles as hepatitis C virus inhibitors
|
|
US8147818B2
(en)
*
|
2008-02-13 |
2012-04-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
|
JP2011517673A
(ja)
*
|
2008-03-27 |
2011-06-16 |
ブリストル−マイヤーズ スクイブ カンパニー |
芳香族ヘテロ環縮合インドロベンザジアゼピンhcvns5b阻害剤
|
|
EP2280978B1
(en)
*
|
2008-03-27 |
2013-04-24 |
Bristol-Myers Squibb Company |
Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors
|
|
US8178523B2
(en)
*
|
2008-03-27 |
2012-05-15 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
US8138171B2
(en)
*
|
2008-03-27 |
2012-03-20 |
Bristol-Myers Squibb Company |
Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors
|
|
EP2271345B1
(en)
|
2008-04-28 |
2015-05-20 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
|
US8133884B2
(en)
*
|
2008-05-06 |
2012-03-13 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
|
CN102159579B
(zh)
|
2008-06-13 |
2015-03-25 |
默沙东公司 |
三环吲哚衍生物及其使用方法
|
|
TWI454476B
(zh)
*
|
2008-07-08 |
2014-10-01 |
Tibotec Pharm Ltd |
用作c型肝炎病毒抑制劑之巨環吲哚衍生物
|
|
EP2540349B1
(en)
|
2008-07-22 |
2014-02-12 |
Merck Sharp & Dohme Corp. |
Pharmaceutical compositions comprising a macrocyclic quinoxaline compound which is an hcv ns3 protease inhibitor
|
|
KR20110042116A
(ko)
|
2008-08-11 |
2011-04-22 |
글락소스미스클라인 엘엘씨 |
알레르기성, 염증성 및 감염성 질환의 치료에서 사용하기 위한 푸린 유도체
|
|
UA103195C2
(uk)
|
2008-08-11 |
2013-09-25 |
Глаксосмитклайн Ллк |
Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
|
|
CN102176911B
(zh)
|
2008-08-11 |
2014-12-10 |
葛兰素史密丝克莱恩有限责任公司 |
新的腺嘌呤衍生物
|
|
UY32099A
(es)
|
2008-09-11 |
2010-04-30 |
Enanta Pharm Inc |
Inhibidores macrocíclicos de serina proteasas de hepatitis c
|
|
JP5669749B2
(ja)
*
|
2008-12-10 |
2015-02-12 |
アキリオン ファーマシューティカルズ,インコーポレーテッド |
ウイルス複製の阻害剤である4−アミノ−4−オキソブタノイルペプチド環状類似体
|
|
JP5723783B2
(ja)
*
|
2008-12-10 |
2015-05-27 |
アキリオン ファーマシューティカルズ,インコーポレーテッド |
ウイルス複製の阻害剤としての新しい4−アミノ−4−オキソブタノイルペプチド
|
|
SG172778A1
(en)
*
|
2008-12-22 |
2011-08-29 |
Hoffmann La Roche |
Heterocyclic antiviral compounds
|
|
US8551973B2
(en)
|
2008-12-23 |
2013-10-08 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
|
NZ593647A
(en)
|
2008-12-23 |
2013-08-30 |
Gilead Pharmasset Llc |
Synthesis of purine nucleosides
|
|
SG172359A1
(en)
|
2008-12-23 |
2011-07-28 |
Pharmasset Inc |
Nucleoside phosphoramidates
|
|
MX2011007195A
(es)
|
2009-01-07 |
2013-07-12 |
Scynexis Inc |
Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
|
|
EP2396329B1
(en)
*
|
2009-02-11 |
2014-10-29 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis c
|
|
US8143244B2
(en)
*
|
2009-02-26 |
2012-03-27 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
|
US20190127365A1
(en)
|
2017-11-01 |
2019-05-02 |
Merck Sharp & Dohme Corp. |
Inhibitors of hepatitis c virus replication
|
|
JP5913091B2
(ja)
|
2009-03-27 |
2016-04-27 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
C型肝炎ウイルス複製の阻害剤
|
|
WO2010114896A1
(en)
*
|
2009-03-31 |
2010-10-07 |
Arqule, Inc. |
Substituted indolo-pyridinone compounds
|
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
|
TWI598358B
(zh)
|
2009-05-20 |
2017-09-11 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
|
US8828930B2
(en)
|
2009-07-30 |
2014-09-09 |
Merck Sharp & Dohme Corp. |
Hepatitis C virus NS3 protease inhibitors
|
|
WO2011098451A1
(en)
|
2010-02-10 |
2011-08-18 |
Glaxosmithkline Llc |
Purine derivatives and their pharmaceutical uses
|
|
BR112012018904A2
(pt)
|
2010-02-10 |
2020-09-01 |
Glaxosmithkline Llc |
composto, adjuvante de vacina, composições imunogênica, de vacina e farmacêutica, e uso de um composto"
|
|
CN102918049A
(zh)
*
|
2010-03-09 |
2013-02-06 |
默沙东公司 |
稠合三环甲硅烷基化合物及其用于治疗病毒性疾病的方法
|
|
JP2013527145A
(ja)
|
2010-03-31 |
2013-06-27 |
ギリード・ファーマセット・エルエルシー |
リン含有活性化剤の立体選択的合成
|
|
TW201136945A
(en)
|
2010-03-31 |
2011-11-01 |
Pharmasset Inc |
Purine nucleoside phosphoramidate
|
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
|
BR112012032889A2
(pt)
|
2010-06-24 |
2015-09-15 |
Janssen R & D Ireland |
preparação do ácido 13-ciclo-hexil-3-metóxi-6-[metil-(2-{2-[metil-(sulfamoil)-amino]-etóxi}-etil)-carbamoil]-7h-indol-[2,1-a]-[2]-benzazepina-10-carboxílico
|
|
JP2013540122A
(ja)
|
2010-09-29 |
2013-10-31 |
メルク・シャープ・エンド・ドーム・コーポレイション |
縮合四環式化合物誘導体およびウィルス疾患治療のためのそれの使用方法
|
|
PT3042910T
(pt)
|
2010-11-30 |
2019-04-16 |
Gilead Pharmasset Llc |
2'-espiro-nucleósidos para utilização na terapia da hepatite c
|
|
EP2658858A4
(en)
|
2010-12-30 |
2014-06-25 |
Enanta Pharm Inc |
MACROCYCLIC INHIBITORS OF HEPATITIS C SERINE PROTEASE PHENANTHRIDINE
|
|
MX2013007677A
(es)
|
2010-12-30 |
2013-07-30 |
Abbvie Inc |
Inhibidores macrociclicos de serina proteasa de hepatitis.
|
|
WO2012122716A1
(en)
|
2011-03-17 |
2012-09-20 |
Merck Sharp & Dohme Corp. |
Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
|
|
US10201584B1
(en)
|
2011-05-17 |
2019-02-12 |
Abbvie Inc. |
Compositions and methods for treating HCV
|
|
CA2840242C
(en)
|
2011-09-16 |
2019-03-26 |
Gilead Sciences, Inc. |
Methods for treating hcv
|
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
|
GB2515942A
(en)
|
2011-10-21 |
2015-01-07 |
Abbvie Inc |
Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
|
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
|
PT107894A
(pt)
|
2011-10-21 |
2014-10-31 |
Abbvie Inc |
Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão.
|
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
|
US10202392B2
(en)
|
2012-04-26 |
2019-02-12 |
Francis Xavier Tavares |
Synthesis of lactams
|
|
AU2013290402A1
(en)
*
|
2012-07-18 |
2015-03-05 |
Bristol-Myers Squibb Holdings Ireland |
Novel methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3-methoxy-5a-((1 r,5s) -3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide
|
|
WO2014110687A1
(en)
|
2013-01-16 |
2014-07-24 |
Merck Sharp & Dohme Corp. |
Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
|
|
KR20200060782A
(ko)
|
2013-01-31 |
2020-06-01 |
길리애드 파마셋 엘엘씨 |
두 항바이러스 화합물의 병용 제형물
|
|
WO2014121417A1
(en)
*
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
|
WO2014121416A1
(en)
*
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
|
WO2014121418A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
|
AU2014227849A1
(en)
|
2013-03-15 |
2015-10-01 |
Achillion Pharmaceuticals, Inc. |
Sovaprevir polymorphs and methods of manufacture thereof
|
|
WO2014145600A1
(en)
|
2013-03-15 |
2014-09-18 |
Achillion Pharmaceuticals, Inc. |
Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
|
|
WO2014145507A1
(en)
|
2013-03-15 |
2014-09-18 |
Achillion Pharmaceuticals, Inc. |
A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
|
|
EP3650014B1
(en)
|
2013-08-27 |
2021-10-06 |
Gilead Pharmasset LLC |
Combination formulation of two antiviral compounds
|
|
WO2015061407A1
(en)
*
|
2013-10-24 |
2015-04-30 |
Francis Xavier Tavares |
Process for synthesis of lactams
|
|
WO2015103490A1
(en)
|
2014-01-03 |
2015-07-09 |
Abbvie, Inc. |
Solid antiviral dosage forms
|
|
WO2015124591A1
(en)
|
2014-02-20 |
2015-08-27 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Pyrrolo[3,2] pyrimidine derivatives as inducers of human interferon
|
|
US10584125B2
(en)
|
2014-11-13 |
2020-03-10 |
Glaxosmithkline Biologicals Sa |
Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions
|
|
RU2020113165A
(ru)
|
2015-12-03 |
2020-06-09 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Циклические пуриновые динуклеотиды в качестве модуляторов sting
|
|
JP2019510802A
(ja)
|
2016-04-07 |
2019-04-18 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
タンパク質調節物質として有用な複素環アミド
|
|
CN113549110B
(zh)
|
2016-04-07 |
2024-08-16 |
葛兰素史密斯克莱知识产权发展有限公司 |
用作蛋白质调节剂的杂环酰胺
|
|
US11192914B2
(en)
|
2016-04-28 |
2021-12-07 |
Emory University |
Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
|
|
CA3063288A1
(en)
|
2017-05-12 |
2018-11-15 |
Mavalon Therapeutics Limited |
Substituted heterocyclic compounds as allosteric modulators of group ii metabotropic glutamate receptors
|
|
JP2020536106A
(ja)
|
2017-10-05 |
2020-12-10 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
Hivの処置に有用なインターフェロン遺伝子の刺激物質(sting)の調節物質
|
|
BR112020006780A2
(pt)
|
2017-10-05 |
2020-10-06 |
Glaxosmithkline Intellectual Property Development Limited |
moduladores do estimulador de genes do interferon (sting)
|
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
|
JP2022533390A
(ja)
|
2019-05-16 |
2022-07-22 |
スティングセラ インコーポレイテッド |
オキソアクリジニル酢酸誘導体および使用方法
|
|
EP3969452A1
(en)
|
2019-05-16 |
2022-03-23 |
Stingthera, Inc. |
Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
|
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
CN114981265B
(zh)
|
2019-12-18 |
2025-01-03 |
Ctxt私人有限公司 |
化合物
|
|
US12274700B1
(en)
|
2020-10-30 |
2025-04-15 |
Accencio LLC |
Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
|